Who
Christopher P. Molineaux
Director
Company insider
Files Form 4 as: Director, Aclaris Therapeutics.
In numbers
- Trades disclosed
- 56
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $38K
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 18 Dec 2015
- Last trade
- 5 Jun 2026
- Last filed
- 8 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 8 Jun 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —11,580 | filing |
| 5 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,580 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,580 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —11,580 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,350 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,987 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,350 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,987 at $0.00 | filing |
| 6 Jun 2025filed 9 Jun 2025 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,793 at $0.00 | filing |
| 6 Jun 2025filed 9 Jun 2025 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —4,793 | filing |
| 5 Jun 2025filed 9 Jun 2025 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,350 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,580 at $0.00 | filing |
| 6 Jun 2024filed 10 Jun 2024 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,750 at $0.00 | filing |
| 6 Jun 2024filed 10 Jun 2024 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,793 at $0.00 | filing |
| 1 Jun 2024filed 4 Jun 2024 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,660 at $0.00 | filing |
| 1 Jun 2024filed 4 Jun 2024 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —4,660 | filing |
| 20 Jun 2023filed 22 Jun 2023 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,500 at $0.00 | filing |
| 20 Jun 2023filed 22 Jun 2023 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | $23K16,500 at $1.41 | filing |
| 15 Jun 2023filed 20 Jun 2023 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —51 at $0.00 | filing |
| 15 Jun 2023filed 20 Jun 2023 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —198 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.